Cargando…
Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients
Autores principales: | Mace, Thomas A, Pitaressi, Jason, Shakya, Reena, Frankel, Wendy, Eubank, Tim, Bekaii-Saab, Tanios, Bloomston, Mark, Phelps, Mitch, Ludwig, Thomas, Ostrowski, Michael, Lesinski, Gregory B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990331/ http://dx.doi.org/10.1186/2051-1426-1-S1-P163 |
Ejemplares similares
-
Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015) -
BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2014) -
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer
por: Mace, Thomas A., et al.
Publicado: (2015) -
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
por: So, Brian J, et al.
Publicado: (2008) -
Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment
por: Mace, Thomas A, et al.
Publicado: (2013)